The new generation of the RIDA®GENE multiplex real-time PCR kits offers a number of improvements—and makes molecular laboratory diagnostics even more efficient and flexible.
R-Biopharm and ELITechGroup announced a worldwide agreement to expand their real-time PCR assay portfolio
Darmstadt, Germany and Puteaux, France, April 19, 2018 – R-Biopharm, a globally active life science company, and ELITechGroup, a leading company in sample-to-result molecular diagnostics, [...]
R-Biopharm AG & Bosch Healthcare Solutions partner to develop molecular diagnostics for automated all-in-one platform
R-Biopharm AG today announced that it has entered into a collaboration with Bosch Healthcare Solutions. Under the agreement, R‑Biopharm AG develops, manufactures and commercializes molecular [...]
As temperatures grow colder, the risk of catching the flu virus rises as well. This year, Australia is experiencing the worst flu epidemic in 15 years. Are Europe and North America also facing [...]
RIDA®GENE Helicobacter pylori is a sensitive and specific real-time PCR assay. It simultaneously detects and differentiates Helicobacter pylori and its resistance to clarithromycin in human [...]
Excellent results of the RIDA®GENE MRSA real-time PCR assay in the external quality assessment program of Instand e.V. Repeatedly, the R-Biopharm AG participated successfully in the INSTAND [...]
The RIDA®GENE real-time PCR assays (RIDA®GENE Flu, RIDA®GENE Flu LC2.0, RIDA®GENE Flu & RSV) successfully detected the suggested vaccination strains for influenca of the 2015/2016 season.
The RIDA®GENE real-time PCR assays for the detection of Influenza (RIDA®GENE Flu, RIDA®GENE Flu LC2.0, RIDA®GENE Flu & RSV) detect the currently circulating drift variant of influenza A (H3N2).